A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
Status:
Completed
Trial end date:
2019-05-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test the hypothesis that treatment with mirikizumab is
superior to placebo in providing clinical benefit to participants with moderate to severe
ulcerative colitis (UC). This study will also investigate how the body processes the drug.